On Apr. 29, 2020, Evotec announced that its Seattle-based subsidiary Just – Evotec Biologics has entered into a partnership with Ology Bioservices for the evaluation and analytical characterisation of antibodies against SARS-CoV-2.

This work falls under a contract awarded to Ology Bio by the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies to develop, and manufacture monoclonal antibodies for treatment and prevention of infections with SARS-CoV-2.